{"id":16993,"date":"2025-10-21T15:05:26","date_gmt":"2025-10-21T08:05:26","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=16993"},"modified":"2025-11-15T16:15:05","modified_gmt":"2025-11-15T09:15:05","slug":"lidocaine-hydrochloride-monohydrate","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/lidocaine-hydrochloride-monohydrate\/","title":{"rendered":"Lidocaine Hydrochloride Monohydrate"},"content":{"rendered":"

Lidocaine Hydrochloride<\/p>\n

(Ph. Eur. monograph 0227)<\/p>\n

C14<\/sub>H23<\/sub>ClN2<\/sub>O,H2<\/sub>O\u00a0 \u00a0 \u00a0 \u00a0288.8\u00a0 \u00a0 \u00a0 \u00a06108-05-0<\/p>\n

Action and use<\/strong><\/p>\n

Local anaesthetic; Class I antiarrhythmic.<\/p>\n

Preparations<\/strong><\/p>\n

Lidocaine Gel<\/p>\n

Lidocaine and Chlorhexidine Gel<\/p>\n

Lidocaine Injection<\/p>\n

Lidocaine and Adrenaline Injection\/Lidocaine and Epinephrine Injection<\/p>\n

Lidocaine Intraocular Injection<\/p>\n

Lidocaine Sterile Solution<\/p>\n

DEFINITION<\/h2>\n

2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide hydrochloride monohydrate.<\/p>\n

Content<\/h2>\n

99.0 per cent to 101.0 per cent (anhydrous substance).<\/p>\n

CHARACTERS<\/h2>\n

Appearance<\/h3>\n

White or almost white, crystalline powder.<\/p>\n

Solubility<\/h3>\n

Very soluble in water, freely soluble in ethanol (96 per cent).<\/p>\n

IDENTIFICATION<\/h2>\n

First identification: B, D.<\/p>\n

Second identification: A, C, D.<\/p>\n

A. Melting point (2.2.14): 74 \u00b0C to 79 \u00b0C, determined without previous drying.<\/p>\n

B. Infrared absorption spectrophotometry (2.2.24).<\/p>\n

Comparison: lidocaine hydrochloride CRS.<\/p>\n

C. To about 5 mg add 0.5 mL of fuming nitric acid R. Evaporate to dryness on a water-bath, cool and dissolve the residue in 5 mL of acetone R. Add 0.2 mL of alcoholic potassium hydroxide solution R. A green colour is produced.<\/p>\n

D. It gives reaction (a) of chlorides (2.3.1).<\/p>\n

TESTS<\/h2>\n

Solution S<\/h3>\n

Dissolve 1.0 g in carbon dioxide-free water R and dilute to 20 mL with the same solvent.<\/p>\n

Appearance of solution<\/h3>\n

Solution S is clear (2.2.1) and colourless (2.2.2, Method II).<\/p>\n

pH (2.2.3)<\/h4>\n

4.0 to 5.5.<\/p>\n

Dilute 1 mL of solution S to 10 mL with carbon dioxide-free water R.<\/p>\n

Related substances<\/h3>\n

Liquid chromatography (2.2.29).<\/p>\n

Test solution: Dissolve 50.0 mg of the substance to be examined in the mobile phase and dilute to 10.0 mL with the mobile phase.<\/p>\n

Reference solution (a): Dissolve 50.0 mg of 2,6-dimethylaniline R (impurity A) in the mobile phase and dilute to 100.0 mL with the mobile phase. Dilute 10.0 mL of the solution to 100.0 mL with the mobile phase.<\/p>\n

Reference solution (b): Dissolve 5 mg of 2-chloro-N-(2,6-dimethylphenyl)acetamide R (impurity H) in the mobile phase and dilute to 10.0 mL with the mobile phase.<\/p>\n

Reference solution (c): Dilute 1.0 mL of the test solution to 10.0 mL with the mobile phase.<\/p>\n

Reference solution (d): Mix 1.0 mL of reference solution (a), 1.0 mL of reference solution (b) and 1.0 mL of reference solution (c), and dilute to 100.0 mL with the mobile phase.<\/p>\n

Column:<\/p>\n

\u2014 size: l = 0.15 m, \u00d8 = 3.9 mm;<\/p>\n

\u2014 stationary phase: end-capped polar-embedded octadecylsilyl amorphous organosilica polymer R (5 \u03bcm);<\/p>\n

\u2014 temperature: 30 \u00b0C.<\/p>\n

Mobile phase: Mix 30 volumes of acetonitrile for chromatography R and 70 volumes of a 4.85 g\/L solution of potassium dihydrogen phosphate R previously adjusted to pH 8.0 with strong sodium hydroxide solution R.<\/p>\n

Flow rate: 1.0 mL\/min.<\/p>\n

Detection: Spectrophotometer at 230 nm.<\/p>\n

Injection: 20 \u03bcL of the test solution and reference solutions (a), (b) and (d).<\/p>\n

Run time: 3.5 times the retention time of lidocaine.<\/p>\n

Identification of impurities: Use the chromatogram obtained with reference solution (a) to identify the peak due to impurity A; use the chromatogram obtained with reference solution (b) to identify the peak due to impurity H.<\/p>\n

Relative retention: With reference to lidocaine (retention time = about 17 min): impurity H = about 0.37; impurity A = about 0.40.<\/p>\n

System suitability: Reference solution (d):<\/p>\n

\u2014 resolution: minimum 1.5 between the peaks due to impurities H and A.<\/p>\n

Limits:<\/p>\n

\u2014 impurity A: not more than the area of the corresponding peak in the chromatogram obtained with reference solution (d) (0.01 per cent);<\/p>\n

\u2014 unspecified impurities: for each impurity, not more than the area of the peak due to lidocaine in the chromatogram obtained with reference solution (d) (0.10 per cent);<\/p>\n

\u2014 total: not more than 5 times the area of the peak due to lidocaine in the chromatogram obtained with reference solution (d) (0.5 per cent);<\/p>\n

\u2014 disregard limit: 0.5 times the area of the peak due to lidocaine in the chromatogram obtained with reference solution (d) (0.05 per cent); do not disregard the peak due to impurity A .<\/p>\n

Water (2.5.12)<\/h4>\n

5.5 per cent to 7.0 per cent, determined on 0.25 g.<\/p>\n

Maximum 0.1 per cent, determined on 1.0 g.<\/p>\n

ASSAY<\/h2>\n

Dissolve 0.220 g in 50 mL of ethanol (96 per cent) R and add 5.0 mL of 0.01 M hydrochloric acid. Carry out a potentiometric titration (2.2.20), using 0.1 M sodium hydroxide. Read the volume added between the 2 points of inflexion.<\/p>\n

1 mL of 0.1 M sodium hydroxide is equivalent to 27.08 mg of C14<\/sub>H23<\/sub>ClN2<\/sub>O.<\/p>\n

STORAGE<\/h2>\n

Protected from light.<\/p>\n

IMPURITIES<\/h2>\n

Specified impurities A.<\/p>\n

Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) B, C, D, E, F, G, H, I, J, K.<\/p>\n

\"Lidocaine<\/p>\n

A. 2,6-dimethylaniline,<\/p>\n

\"Lidocaine<\/p>\n

B. 2-(diethylazinoyl)-N-(2,6-dimethylphenyl)acetamide (lidocaine N -oxide),<\/p>\n

\"Lidocaine<\/p>\n

C. N-(2,6-dimethylphenyl)acetamide,<\/p>\n

\"Lidocaine<\/p>\n

D. N-(2,6-dimethylphenyl)-2-(ethylamino)acetamide,<\/p>\n

\"Lidocaine<\/p>\n

E. 2-2\u2032-(azanediyl)bis[N-(2,6-dimethylphenyl)acetamide],<\/p>\n

\"Lidocaine<\/p>\n

F. 2-(diethylamino)-N-(2,3-dimethylphenyl)acetamide,<\/p>\n

\"Lidocaine<\/p>\n

G. N-(2,6-dimethylphenyl)-2-[(1-methylethyl)amino]acetamide,<\/p>\n

\"Lidocaine<\/p>\n

H. 2-chloro-N-(2,6-dimethylphenyl)acetamide,<\/p>\n

\"Lidocaine<\/p>\n

I. 2-(diethylamino)-N-(2,4-dimethylphenyl)acetamide,<\/p>\n

\"Lidocaine<\/p>\n

J. 2-(diethylamino)-N-(2,5-dimethylphenyl)acetamide,<\/p>\n

\"Lidocaine<\/p>\n

K. N-(2,6-dimethylphenyl)-2-(ethylmethylamino)acetamide.<\/p>\n","protected":false},"excerpt":{"rendered":"

Lidocaine Hydrochloride (Ph. Eur. monograph 0227) C14H23ClN2O,H2O\u00a0 \u00a0 \u00a0 \u00a0288.8\u00a0 \u00a0 \u00a0 \u00a06108-05-0 Action and use Local anaesthetic; Class I antiarrhythmic. Preparations Lidocaine Gel Lidocaine and Chlorhexidine Gel Lidocaine Injection Lidocaine and Adrenaline Injection\/Lidocaine and Epinephrine Injection Lidocaine Intraocular Injection Lidocaine Sterile Solution DEFINITION 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide hydrochloride monohydrate. Content 99.0 per cent to 101.0 per cent…<\/p>\n","protected":false},"author":2,"featured_media":17011,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-16993","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/16993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=16993"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/16993\/revisions"}],"predecessor-version":[{"id":17013,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/16993\/revisions\/17013"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/17011"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=16993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=16993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=16993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}